English to Russian Medical Medical: Pharmaceuticals

Overall Benefit Risk Assessment
There is evidence that HER2-targeted therapies have the potential to be more efficacious than the current SOC for patients with HER2+ 1L mCRC, where an ongoing unmet need exists.
The preclinical and clinical data summarized above support the proposed evaluation of tucatinib, trastuzumab, and mFOLFOX6 in this patient population.